I know you don't follow IMU closely anymore which is why don't know the recent development of IMU's IP and why the shares are cheap right now considering the fundamental achievement in the last 16 months which the market hasn't now value and actually sold the pps lower than the 4c last time. You invest in RAC for these kind of IP development, don't you?????
Like I said and as evident by what LC said, IMU had $45M at the start of this year with expenditure of $15M per quarter with $8M of those spent on R&D so they didn't need to do a CR in December last year but would have right now but PH got a good deal with the CN and warrant at 5c considering the pps was around 3.5c at that time. And like I said, this will be dependent on the clinical trial updates for VAXINIA and OASIS expected to be released this quarter as IMU has mentioned, the market is clearly showing more interest in these IP compared to Azer-Cel. Given the current development of Azer-Cel, MC of $200M for Azer-Cel is cheap especially with available fund of $131M at the start of the year and that's telling you something.
IMU Price at posting:
2.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)